Recent Updates
Recently added Catalysts

Eocene Ltd.

EOCNFDA catalysts, PDUFA dates & pipeline intelligence
$2.46
▼ -0.07 · -2.77%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full EOCN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
10.16 K
Value Traded
24.32 K
Short % Float
0.82%
Days to Cover
1.3
-0.81%Week
-13.68%1 Month

Cash Data

Unlock EOCN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.56 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
1.04 M
Float Shares
1.02 M
Insiders
2.43%
Institutions
3.44%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every EOCN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

EOCN Catalyst Timeline

Dated clinical, regulatory and corporate events for Eocene Ltd.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Eocene Ltd.

6Total events
3Upcoming
2Tier-1 (high impact)
2026 to 2027Coverage

Upcoming catalysts 2

T2Milestone Payment
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
CG-100

Event history 3

▲Partnership / LicenseAramcholCorporate
Galmed (Eocene subsidiary) and Barcode Nanotech report progress in ongoing Aramchol LNP collaboration
liver and GI tumorssource ↗
▲Preclinical PoCAramcholPreclinical
Novel tumor microenvironment-targeted LNP formulation of Aramchol developed with Barcode Nanotech
liver and GI tumors (tumor microenvironment)source ↗
▲Partnership / LicenseCG-100Corporate
First European commercial distribution agreement with Hospital Line for CG-100 in Greece and Cyprus
colorectal surgery (protection of colorectal anastomoses, reduction of diverting stomas)source ↗
Unlock the full EOCN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How EOCN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all EOCN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 68%
Micro Cap
(rank 493 of 725)
Percentile Rank
Showing 1 of 5 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Aramchol Small MoleculesCompletedNCT04480827Hepatic ImpairmentPhase 1 COMPLETED 57Mar 24, 2022
Unlock the EOCN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every EOCN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every EOCN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock EOCN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full EOCN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in EOCN for Q3 2026.
Unlock every fund holding EOCN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in EOCN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see EOCN ownership
Insider and institutional ownership, quarter by quarter.

EOCN Short Interest

Shares sold short, counted twice a month.

0.82%
Short % of Float
of tradable shares sold short
8.4K
Shares Sold Short
+11.7% vs prior count
1.3 Low
Days to Cover
trading days of normal volume to buy every short share back
6.4K
Avg Daily Volume
the average used for days to cover
Unlock EOCN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock EOCN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live EOCN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock EOCN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How EOCN ranks across every disease it competes in

Competitive Position is a premium feature
See how EOCN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

EOCN News

About Eocene Ltd.

6 employees eocn.com
BIOPHARMAWATCH ELITE
Trade the next EOCN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime